Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2026-03-24 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物2026年度”提质增效重回报”行动方案
Annual Report Classification · 95% confidence The document is a detailed action plan for the year 2026 by 迈威（上海）生物科技股份有限公司, covering extensive information about the company's R&D pipeline, commercialization strategies, governance, investor relations, share repurchase, and financing activities. It includes financial data such as sales revenue for 2025, descriptions of clinical trials, regulatory approvals, governance improvements, and capital structure optimization. The document is comprehensive, with substantive financial and operational data, and is dated March 24, 2026. It is not a brief announcement or a certification but a full report outlining company activities and performance over a fiscal year. This matches the characteristics of an Annual Report (10-K) rather than an interim report or other filings. Therefore, the appropriate classification is Annual Report (10-K).
2026-03-24 Chinese
迈威生物2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2025 by 迈威（上海）生物科技股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025, including financial and non-financial internal control defects, audit opinions, scope of evaluation, standards for defect recognition, and remediation status. The content is focused on internal control evaluation rather than full financial statements or annual performance. The document length is 4263 characters, which is relatively short but contains substantive evaluation content rather than just an announcement. This type of report is typically classified as an Audit Report / Information (AR) because it deals with internal control evaluation and audit opinions on internal controls, not a full Annual Report (10-K) or Interim Report (IR). It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains detailed evaluation content, not just a notice or certification. Therefore, the best fit is AR (Audit Report / Information).
2026-03-24 Chinese
迈威生物关于续聘公司2026年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's audit firm for the fiscal year 2026. It details the background, qualifications, and integrity of the audit firm (Ernst & Young Hua Ming), the audit committee's opinion, and the board's approval. It does not contain any financial statements or audit results but is a formal notice about the audit firm appointment process and pending shareholder approval. The document length is 2512 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this fits the category of an Audit Report / Information announcement about the audit firm appointment rather than the audit report itself.
2026-03-24 Chinese
迈威生物2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2025 Annual General Meeting (AGM) of 迈威(上海)生物科技股份有限公司. It includes detailed meeting instructions, agenda, and multiple proposals to be voted on at the AGM, such as approval of the 2025 Annual Report, profit distribution plan, reappointment of the audit firm, and the 2025 Board of Directors work report. The content is focused on the meeting logistics, voting procedures, and agenda items rather than the full annual report or financial statements themselves. The document is comprehensive and lengthy (15,000 characters), consistent with detailed AGM materials rather than a brief announcement. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting.
2026-03-24 Chinese
迈威生物第二届董事会第二十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 29th meeting of the second board of directors of Maiwei (Shanghai) Biotechnology Co., Ltd. It includes approvals of the 2025 annual report, audit report, fundraising usage reports, internal control reports, independent directors' reports, profit distribution plan, appointment of the audit firm for 2026, ESG report, board and general manager work reports, and other governance-related reports. The document also states that the full 2025 annual report and other reports are published separately on the Shanghai Stock Exchange website. The document is not the annual report itself but a board meeting resolution announcement regarding the approval of various reports and plans, including the annual report. It is a formal board/management information disclosure about board decisions and approvals. Therefore, the appropriate classification is Board/Management Information (MANG).
2026-03-24 Chinese
迈威生物2025年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2025年度董事会审计委员会履职情况报告" which translates to "2025 Annual Board Audit Committee Performance Report." It details the audit committee's activities, meetings, supervision of external auditors, review of financial reports, internal controls, and internal audit work for the year 2025. The document is a report on the audit committee's duties and oversight rather than a full audit report or annual report itself. It is not a short announcement or a certification letter but a substantive report on the audit committee's performance and oversight activities. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related oversight information, excluding full annual reports. The document length is 3648 characters, which is relatively short but contains detailed content about audit committee activities, not just an announcement. Therefore, the best classification is AR with high confidence.
2026-03-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.